Epidemiology and risk factors of postherpetic neuralgia worldwide: protocol for a systematic review and meta-analysis

全球带状疱疹后神经痛的流行病学和危险因素:系统评价和荟萃分析方案

阅读:1

Abstract

INTRODUCTION: Postherpetic neuralgia (PHN) is a debilitating complication of herpes zoster (HZ) that significantly impairs quality of life, disrupting sleep, daily activities and work capacity. Globally, PHN represents a major public health challenge, with marked heterogeneity in its epidemiological patterns across different regions and demographic groups. The escalating incidence of both HZ and PHN underscores the urgent need to elucidate modifiable and non-modifiable risk factors, which is critical for implementing targeted prevention strategies and optimising therapeutic interventions. Although previous studies have examined PHN risk factors, there remains a paucity of comprehensive, up-to-date systematic analyses evaluating its global epidemiological trends and associated determinants. This protocol presents the methodology of a planned systematic review to assess an updated global estimate of PHN epidemiology and synthesises critical risk factors associated with PHN prevalence or severity. METHODS AND ANALYSIS: This systematic review and meta-analysis will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We will search MEDLINE/PubMed, Embase, Web of Science, CENTRAL, PsycINFO, Google Scholar, CNKI, Wanfang and CBM for English/Chinese studies published from inception through April 2025. Eligible studies will include adults (≥18 years) with HZ or PHN that report PHN prevalence/incidence or relevant risk factors (eg, age, vaccination status, acute pain severity, comorbidities). Two reviewers will independently screen records, extract data (including study characteristics, demographics, risk factors and pain metrics) and assess risk of bias using Joanna Briggs Institute tools and ROBINS-I. Random-effects meta-analyses (R V.4.0) will pool PHN prevalence (logit-transformed Wilson scores) and ORs for risk factors, with subgroup analyses by geography, income level, clinical/demographic factors. Heterogeneity (I²≥50%) will trigger meta-regression or narrative synthesis. Sensitivity analyses will address bias robustness. ETHICS AND DISSEMINATION: Ethics committee approval is not required. The results of the review will be published through an open access journal. PROSPERO REGISTRATION NUMBER: CRD42024510329.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。